SavedAdd your journal

Journals / Turkish Journal of Gastroenterology / 1999 / Cilt: 10 - Sayı: 4

The effects of non-steroidal anti-inflammatory drug ( NSAID ) use on serum gastrin, pepsinogen-1 levels and Helicobacter pylori status

Kısa süreli nonsteroidal antiinflamatuvar ilaç kullanımının serum gastrin ve pepsinojen-1 seviyeleri ile Helicobacter pylori üzerine olan etkileri

Bülent KARASU
Muhsin KAYA
Ali ÖZDEN
Pages
396–402
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The presence of H. pylori has a role in the development of NSAID induced mucosal changes but pathophysiologic mechanism is not through changes in serum gastrin or pepsinogen-1 levels.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Serious adverse events can be seen in the gastrointestinal tract and kidneys of patients treated with NSAIDs.
📊
Key Findings & Data:The purpose of this study was to demostrate whether a relationship exists between NSAID induced gastrointestinal mucosal injury and the presence of H. pylori and correlation of serum gastrin and pepsinogen-1 levels with the development of mucosal injury.
💡
Conclusion & Impact:The presence of H. pylori has a role in the development of NSAID induced mucosal changes but pathophysiologic mechanism is not through changes in serum gastrin or pepsinogen-1 levels.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Anti-enflamatuvar ajanlar · steroid olmayan · Gastrointestinal hastalıklar

Abstract

Serious adverse events can be seen in the gastrointestinal tract and kidneys of patients treated with NSAIDs. The purpose of this study was to demostrate whether a relationship exists between NSAID induced gastrointestinal mucosal injury and the presence of H. pylori and correlation of serum gastrin and pepsinogen-1 levels with the development of mucosal injury. The study included 30 patients (11 female and 9 male) with a mean age of 36,6 (18-65) years. Who were randomised into three comparable groups and either aspirin 300mg/day, nabumetone, 1000 mg/day, or placebo was given orally for 10 days. Upper gastrointestinal tract endoscopy was performed and symptoms evaluated in each group before and after the treatment period. H. pylori was found to be positive in 24 (80%), patients prior to treatment. Gastrointestinal symptoms before and after 10 days of NSAID treatment were not significantly different (p>0.05) but patients treated with either aspirin (COX-1 inhibitor) or nabumetone (COX-2 inhibitor) had a significant (p<0.05) increase in mucosal injury as demonstrated by endoscopy, when compared to pretreatment findings. No difference was found between the severity or type of mucosal lesions induced either by aspirin or nabumetone. Fasting serum gastrin and pepsinogen-1 levels before and after NSAID treatment were found to be similar. NSAID induced mucosal changes were seen more frequently (p<0.05 ) in patients with H. pylori positi-vity when compared to those with negative values. In summary, short term NSAID treatment induces asymptomatic mucosal changes. The presence of H. pylori has a role in the development of NSAID induced mucosal changes but pathophysiologic mechanism is not through changes in serum gastrin or pepsinogen-1 levels.

Özet

Nonsteroidal antiinflamatuvar ilaç (NSAİİ) kullanımına bağlı olarak özofagus, mide, duodenum ve böbreklerde önemli yan etkiler görülebilir. Sunulan bu çalışmanın amacı, Helicobacter pylori (H. pylori) infeksiyonunun NSAİİ kullanımına bağlı oluşabilecek gastroduodenal mukozal hasar oluşumundaki etkisinin belirlenmesi ve gelişen bu hasarın açlık serum gastrin ve pepsinojen-I seviyeleriyle ilişkisinin ortaya konmasıdır. Çalışmaya yaş ortalamaları 36.6 (18-66 yaş) olan 11E ve 19K toplam 30 olgu dahil edildi. Bu kişiler üç eşit gruba bölünerek her gruba 10 gün süreyle Aspirin 300 mg/gün, plasebo ve Nabumeton 1000 mg/gün ağız yolu ile verildi. Olgularda NSAİİ veya plasebo öncesi ve sonrası olmak üzere dispeptik ve endoskopik skorlamalar yapıldı. Ayrıca, H. pylori varlığı ile açlık serum gastrin ve pepsinojen-I seviyeleri araştırıldı. Başlangıçta 30 hastanın 24'ünde (%80) H. pylori(+) iken; 6'sında (%20) H. pylori(-) bulundu. NSAİİ verilmesi ile gastrointestinal semptomlarda anlamlı artış saptanmadı (p>0.05). Buna karşılık endoskopik olarak hem COX-1 inhibitörü olan Aspirin verilen olgularda, hem de selektif COX-2 inhibitörü olarak bildirilen Nabumeton verilen olgularda anlamlı derecede hasar tespit edildi (p 0.05). H. pylori pozitifliği ile NSAİİ kullanımı sonrası mukozal hasar gelişimi arasında anlamlı ilişki saptandı (p<0.01). Sonuç olarak kısa süreli NSAİİ kullanımının asemptomatik gastroduodenal mukozal hasar oluşturduğu, H. pylori infeksiyonunun gelişen hasar üzerine etkili olduğu, ancak bu hasarın belirlenmesinde açlık serum gastrin ve pepsinojen-I seviyelerinin iyi bir belirleyici olmadığı saptandı.

🔖

Cite This Article

KARASU, B., KAYA, M., ÖZDEN, A. (1999). The effects of non-steroidal anti-inflammatory drug ( NSAID ) use on serum gastrin, pepsinogen-1 levels and Helicobacter pylori status. Turkish Journal of Gastroenterology, Cilt: 10 - Sayı: 4, 396–402. https://ajindex.com/articles/411398

References (15)

  1. Özden A. İşte Helicobacter pylori, gastrit, peptik ülser. Türk Gastroenteroloji derneği yayını 1996
  2. Jouzeau JY, Terlain B, Abid A, et al. Cyclo-oxygenase isoenzymes. Drugs 1997; 53: 563-82
  3. Siegle I, Klein T, Backman JT, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human synovial tissue. Arthritis & Rheum 1998; 41: 122-9
  4. Copeland RA, Wiliams JM, Giannaras J, et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad. Sci 1994; 91: 11202-6
  5. Griswold DE, Adams JL. Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): Rationale for selective inhibition and progress to date. Med Res Rev 1996; 16: 181-206
  6. Helicobacter pylori el kitabı. Nobel İla 1997
  7. Helicobacter pylori in peptic ulcer disease. NIH consensus conference. JAMA 1994; 27: 65-9
  8. Loeb DS, Talley NJ, Ahlqist DA, et al. Long-term nonsteroidal antiinflammatory drug use and gastroduodenal injury: The role of Helicobacter pylori. Gastroenterology 1992; 102: 1899-905
  9. Li EKM, Sung JJY, Ling TKW, et al. Helicobacter pylori infection increases the risk of peptic ulcers in chronic users of non-steroidal anti-inflammatory drugs. Scand J Rheumatol 1996; 25: 42-6
  10. Larkai EN, Smith L, Lidsky MD, et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82: 1153-8
  11. Hawkey CJ. Non-steroidal anti-inflammatory drug gastropathy: Causes and treatment. Scand J Gastroenterol 1996; 31: 124-7
  12. Lane NE. Pain management in osteoarthritis: The role of COX-2 Inhibitors. J Rheumatol 1997; 24: 20-4 13) Kemppainen H, Raiha I, Sourande L et al. Serum pepsinogen-I and gastrin in peptic ulcer patients using non-steroidal anti-inflammatory drugs. Hepato-Gastroentero-logy 1997; 44: 1143-6
  13. Santucci L, Fiorucci S, Patoıa L, et al. Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori Infection and high levels of serum pepsinogens. Dig Dis Sci 1995; 40: 2074-80
  14. Bağcı S, Çakırbay H, Demiriz M, et al. Helikobakter pilori infeksiyonu ile nonsteroidal anti-inflamatuvar ilaçlara bağlı gastroduodenal mukozal hasar ilişkisi. Türk J Gastroenterol 1995; 6: 242-7
  15. Lanza FL., Evans DG., GrahaDY. Effrect of Helicobacter pylori infection on the severity of gastroduodenal mucosal injury after the acute administration of Naproxen or Aspirin to normal volunters